IRIS

The PURE-01 study (NCT02736266) pioneered the neoadjuvant immune-checkpoint inhibitor (ICI) therapy before radical cystectomy (RC) in patients with muscle-invasive urothelial bladder carcinoma (MIBC). We herein present the survival outcomes after a median follow-up of three years.

Neoadjuvant pembrolizumab and radical cystectomy in patients with muscle-invasive urothelial bladder cancer: 3-year median follow-up update of PURE-01 trial

Basile, Giuseppe;Bandini, Marco;Crupi, Emanuele;Colecchia, Maurizio;Nocera, Luigi;Briganti, Alberto;Montorsi, Francesco;Necchi, Andrea
2022-01-01

Abstract

The PURE-01 study (NCT02736266) pioneered the neoadjuvant immune-checkpoint inhibitor (ICI) therapy before radical cystectomy (RC) in patients with muscle-invasive urothelial bladder carcinoma (MIBC). We herein present the survival outcomes after a median follow-up of three years.
2022
Inglese
OF1
OF8
Epub ahead of print
2-s2.0-85139994791
WOS:000893069400001
36190522
none
16
info:eu-repo/semantics/article
262
Basile, Giuseppe; Bandini, Marco; Gibb, Ewan A; Ross, Jeffrey S; Raggi, Daniele; Marandino, Laura; Costa de Padua, Tiago; Crupi, Emanuele; Colombo, Re...espandi
1 Contributo su Rivista::1.1 Articolo in rivista
1.1 Articolo in rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11768/132688
Citazioni
  • ???jsp.display-item.citation.pmc??? 49
  • Scopus 89
  • ???jsp.display-item.citation.isi??? 89
social impact